Abstract:Background The association between inflammation and major depressive disorder (MDD) remains poorly understood, given the heterogeneity of patients with MDD. Aims We investigated inflammatory markers, such as interleukin (IL)-6, high-sensitivity C reactive protein (hsCRP) and tumour necrosis factor-α (TNF-α) in melancholic, atypical and anxious depression and explored whether baseline inflammatory protein levels could indicate prognosis. Methods The sample consisted of participants (aged 18–55 years) from a previously reported multicentre randomised controlled trial with a parallel-group design registered with ClinicalTrials.gov, including melancholic (n=44), atypical (n=37) and anxious (n=44) patients with depression and healthy controls (HCs) (n=33). Subtypes of MDD were classified according to the 30-item Inventory of Depressive Symptomatology, Self-Rated Version and the 17-item Hamilton Depression Rating Scale. Blood levels of TNF-α, IL-6 and hsCRP were assessed using antibody array analysis. Results Patients with MDD, classified according to melancholic, atypical and anxious depression subtypes, and HCs did not differ significantly in baseline TNF-α, IL-6 and hsCRP levels after adjustment. In patients with anxious depression, hsCRP levels increased significantly if they experienced no pain (adjusted (adj.) p=0.010) or mild to moderate pain (adj. p=0.038) compared with those with severe pain. However, the patients with anxious depression and severe pain showed a lower trend in hsCRP levels than patients with atypical depression who experienced severe pain (p=0.022; adj. p=0.155). Baseline TNF-α (adj. p=0.038) and IL-6 (adj. p=0.006) levels in patients in remission were significantly lower than those in patients with no remission among the participants with the atypical depression subtype at the eighth-week follow-up. Conclusions This study provides evidence of differences in inflammatory proteins in patients with varied symptoms among melancholic, atypical and anxious depression subtypes. Further studies on the immunoinflammatory mechanism underlying different subtypes of depression are expected for improved individualised therapy. Trial registration number NCT03219008 .

The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder

Linking peripheral IL-6, IL-1 and hypocretin-1 with cognitive impairment from major depression

Fluoxetine Treatment for Major Depression Decreases the Plasma Levels of Cytokines

Association of Anhedonia with Brain-Derived Neurotrophic Factor and Interleukin-10 in Major Depressive Disorder

Peripheral Cytokine Levels and Response to Antidepressant Treatment in Depression: a Systematic Review and Meta-Analysis

The Plasma IL-18, MIP-1α, MCP-1, SDF-1 and Rantes in Patients with Majior Depression

Inflammatory cytokines, cognition, and response to antidepressant treatment in patients with major depressive disorder

Changes in the Serum Levels of Inflammatory Cytokines in Antidepressant Drug-Naïve Patients with Major Depression

The Changes In, and Relationship Between, Plasma Nitric Oxide and Corticotropin‐releasing Hormone in Patients with Major Depressive Disorder

Association between inflammatory cytokines and symptoms of major depressive disorder in adults

Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression.

Sex differences in the association of plasma cytokines and neurocognition in first-episode major depressive disorder

Inflammatory cytokines, complement factor H and anhedonia in drug-naïve major depressive disorder

The Combination of Serum BDNF, Cortisol and IFN-Gamma Can Assist the Diagnosis of Major Depressive Disorder

Tumor Necrosis Factor- Variations in Patients With Major Depressive Disorder Before and After Antidepressant Treatment

Tumor Necrosis Factor-α Variations in Patients With Major Depressive Disorder Before and After Antidepressant Treatment

Development of Machine-Learning-driven Signatures for Diagnosing and Monitoring Therapeutic Response in Major Depressive Disorder Using Integrated Immune Cell Profiles and Plasma Cytokines

A Preliminary Investigation on Plasma Cell Adhesion Molecules Levels by Protein Microarray Technology in Major Depressive Disorder

Cytokine profile in first-episode drug-naïve major depressive disorder patients with or without anxiety

TNF-α, IL-6 and hsCRP in patients with melancholic, atypical and anxious depression: an antibody array analysis related to somatic symptoms

An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks